Results 331 to 340 of about 152,172 (364)

Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza.

JAMA Netw Open
Wee LE, Lim JT, Ho RWL, Chiew CJ, Lye DCB, Tan KB.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
E. Walsh, Gonzalo Pérez Marc, A. Zareba, A. Falsey, Q. Jiang, Michael Patton, F. Polack, C. Llapur, P. A. Doreski, Kumar Ilangovan, M. Rämet, Yasushi Fukushima, Nazreen Hussen, L. Bont, Jose Cardona, E. Dehaan, Giselle Castillo Villa, M. Ingilizova, D. Eiras, T. Mikati, Rupal N Shah, Kathy Schneider, David Cooper, K. Koury, M. Lino, A. Anderson, K. Jansen, K. Swanson, A. Gurtman, W. Gruber, B. Schmoele-Thoma   +30 more
semanticscholar   +1 more source

RSV through the COVID‐19 pandemic: Burden, shifting epidemiology, and implications for the future

Pediatric Pulmonology, 2023
Respiratory syncytial virus (RSV) represents a major global healthcare burden, particularly in those under 5 years of age. There is no available vaccine, with treatment limited to supportive care or palivizumab for high‐risk children.
R. Stein, H. Zar
semanticscholar   +1 more source

RSV Epidemiology in Australia Before and During COVID-19.

Pediatrics, 2022
BACKGROUND AND OBJECTIVES COVID-19 public health measures have altered respiratory syncytial virus (RSV) epidemiology, resulting in an unseasonal summer epidemic in Australia in 2020.
G. Saravanos, Nan Hu, N. Homaira, D. Muscatello, A. Jaffe, A. Bartlett, N. Wood, W. Rawlinson, A. Kesson, R. Lingam, P. Britton   +10 more
semanticscholar   +1 more source

Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic

Pediatrics, 2021
An unexpected positive outcome of the coronavirus disease 2019 pandemic has been the marked decline in illness associated with other respiratory viruses, likely due to the widespread use of masks and social distancing.
R. Agha, J. Avner
semanticscholar   +1 more source

Predicting the RSV Surge: Pediatric RSV Patterns of the COVID Pandemic

Pediatric Infectious Disease Journal, 2023
Historically, respiratory syncytial virus (RSV) infection trends have been predictable. The COVID-19 pandemic and associated precautions impacted RSV disease patterns. RSV infection trends during the first year of the COVID-19 pandemic may have predicted the 2022 surge in pediatric RSV infections.
Sidney Zven, Madeline Dorr, Allison M. W. Malloy, Apryl Susi, Cade M. Nylund, Elizabeth Hisle-Gorman   +5 more
openaire   +2 more sources

Comparative study of RSV rescue from RSV‐transformed mammalian cells [PDF]

International Journal of Cancer, 1971
AbstractAll individual heterokaryons obtained by fusion of cells of the five different mammalian RSV‐transformed virogenic cells with indicator chicken fibroblasts produced infectious RSV. In contrast, non‐virogenic mammalian cells derived from tumours which arose in mice injected with RSV did not give rise to infectious RSV, even when fused with ...
Vlasta Sovová, L. Donner, O. Machala, J. Svoboda   +3 more
openaire   +2 more sources

Health economics and RSV

Paediatric Respiratory Reviews, 2009
An economic analysis was performed in Spain to evaluate the efficiency (cost-effectiveness) of palivizumab in preventing severe RSV infection in premature infants with GA 32-35 and two or more risk factors (RF). The design was a decision tree model using data from the scientific literature and the FLIP I and FLIP II studies IRIS Study Group.
Pablo Lázaro y de Mercado, Xavier Carbonell-Estrany   +1 more
openaire   +2 more sources